The long-term outcome of patients with polycystic liver disease treated with lanreotide.

Abstract

BACKGROUND:

Polycystic liver disease (PLD) is a phenotypical expression of autosomal dominant polycystic kidney disease and isolated polycystic liver disease. Somatostatin analogues, such as lanreotide, reduce polycystic liver volume.

AIM:

To establish long-term outcome and safety of lanreotide.

METHODS:

This was an open-label, observational extension study of a 6-month, randomised, placebo-controlled trial with lanreotide (120 mg/month) in PLD. The length of total treatment was 12 months. Primary endpoint was relative change in liver volume, as determined by CT-volumetry after 12 months of treatment. We offered patients a CT scan 6 months after stopping lanreotide.

RESULTS:

A total of 41/54 (76%) patients participated in the extension study. Liver volume decreased by 4% (IQR -8% to -1%) after 12 months of treatment. The greatest effect was observed during the first 6 months of treatment (decrease of 4% (IQR -6% to -1%)). Liver volume remained unchanged during the following 6 months. We found that liver volume increased by 4% (IQR 0-6%) 6 months after end of treatment (n = 22).

CONCLUSIONS:

Lanreotide reduces liver volume within the first 6 months of treatment and the beneficial effect is maintained in the following 6 months. Stopping results in recurrence of polycystic liver growth. This suggests that continuous use of lanreotide is needed to maintain its effect.

• Authors: M Chrispijn, F Nevens, T J G Gevers, R Vanslembrouck, M G H van Oijen, W Coudyzer, A L Hoffmann, H M Dekker, R A de Man, L van Keimpema, J P H Drenth
• Journal: Alimentary pharmacology & therapeutics (Aliment Pharmacol Ther) Vol. 35 Issue 2 Pg. 266-74 (Jan 2012) ISSN: 1365-2036 [Electronic] England
• PMID: 22111942 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: © 2011 Blackwell Publishing Ltd.

Chemical References

• Antineoplastic Agents
• Peptides, Cyclic
• lanreotide
• Somatostatin

Topics

• Adult
• Antineoplastic Agents (therapeutic use)
• Cysts (drug therapy, physiopathology)
• Female
• Humans
• Liver (drug effects)
• Liver Diseases (drug therapy, physiopathology)
• Liver Function Tests
• Male
• Middle Aged
• Peptides, Cyclic (therapeutic use)
• Somatostatin (analogs & derivatives, therapeutic use)
• Statistics as Topic
• Time Factors
• Treatment Outcome